Intratumoral injection of immature dendritic cells enhances antitumor effect of hyperthermia using magnetic nanoparticles

International Journal of Cancer

Volumn 116, Issue 4, 2005, Pages 624-633

  Tanaka, Kouji ^a   Ito, Akira ^a   Kobayashi, Takeshi ^a   Kawamura, Tatsuyoshi ^b   Shimada, Shinji ^b   Matsumoto, Kazuhiko ^c   Saida, Toshiaki ^c   Honda, Hiroyuki ^a  

^a NAGOYA UNIVERSITY   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antitumor immunity; Dendritic cell; Hyperthermia; Magnetite cationic liposome; Melanoma

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; HEAT SHOCK PROTEIN 70; LIPOSOME; MAGNETITE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL DEATH; CELL MATURATION; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HYPERTHERMIC THERAPY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SECRETION; SPLEEN CELL; TUMOR IMMUNITY; TUMOR REGRESSION;

ANIMALS; CATIONS; DENDRITIC CELLS; ELECTROMAGNETICS; FERROSOFERRIC OXIDE; HSP70 HEAT-SHOCK PROTEINS; HYPERTHERMIA, INDUCED; IRON; LIPOSOMES; MELANOMA; MICE; NANOSTRUCTURES; OXIDES; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 23244444110     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21061     Document Type: Article

References (47)

1. van der Zee J. Heating the patient: a promising approach? Ann Oncol 2002;13:1173-84.
2. Abe M, Hiraoka M, Takahashi M, Egawa S, Matsuda C, Onoyama Y, Morita K, Kakehi M, Sugahara T. Multi-institutional studies on hyperthermia using an 8-MHz radiofrequency capacitive heating device (Thermotron RF-8) in combination with radiation for cancer therapy. Cancer 1986;58:1589-95.
3. Jordan A, Wust P, Fahling H, John W, Hinz A, Felix R. Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia. Int J Hyperthermia 1993;9:51-68.
4. Minamimura T, Sato H, Kasaoka S, Saito T, Ishizawa S, Takemori S, Tazawa K, Tsukada K. Tumor regression by inductive hyperthermia combined with hepatic embolization using dextran magnetite-incorporated microspheres in rats. Int J Oncol 2000;16:1153-8.
5. Shinkai M, Matsui M, Kobayashi T. Heat properties of magnetoliposomes for local hyperthermia. Jpn J Hyperthermic Oncol 1994;10: 168-77.
6. Shinkai M, Yanase M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Intracellular hyperthermia for cancer using magnetite cationic liposomes: in vitro study. Jpn J Cancer Res 1996;87:1179-83.
7. Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J. Kobayashi T. Intracellular hyperthermia for cancer using magnetite cationic liposomes: ex vivo study. Jpn J Cancer Res 1997;88: 630-2.
8. Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Intracellular hyperthermia for cancer using magnetite cationic liposome: an in vivo study. Jpn J Cancer Res 1998;89:463-9.
9. Suzuki M, Shinkai M, Honda H, Kobayashi T. Anti-cancer effect and immune induction by hyperthermia of malignant melanoma using magnetite cationic liposomes. Melanoma Res 2003;13:129-35.
10. Ito A, Tanaka K, Honda H, Abe S, Yamaguchi H, Kobayashi T. Complete regression of mouse mammary carcinoma with a size greater than 15 mm by frequent repeated hyperthermia using magnetite nanoparticles. J Biosci Bioeng 2003;96:364-9.
11. Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Antitumor immunity induction by intracellular hyperthermia using magnetite cationic liposomes. Jpn J Cancer Res 1998;89:775-82.
12. Schlesinger MJ. Heat shock proteins. J Biol Chem 1990;265:12111-4.
13. Mosser DD, Caron AW, Bourget L, Meriin AB, Sherman MY, Morimoto RI, Massie B. The chaperon function of hsp 70 is required for protection against stress-induced apoptosis. Mol Cell Biol 2000; 20:7146-59.
14. Srivastava PK, Menoret A, Basu S, Binder R, Quade K. Heat shock proteins come of age: primitive functions acquired new roles in an adaptive world. Immunity 1998;8:657-65.
15. Menoret A, Chandawarkar R. Heat-shock protein-based anticancer immunotherapy: An idea whose time has come. Semin Immunol 1998;25:654-60.
16. Castelli C, Ciupitu AM, Rini F, Rivoltini L, Mazzocchi A, Kiessling R, Parmiani G. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res 2001;61: 222-7.
17. Ito A, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia. Cancer Immunol Immunother 2001;50:515-22.
18. Ito A, Shinkai M, Honda H, Yoshikawa K, Saga S, Wakabayashi T, Yoshida J, Kobayashi T. Heat shock protein 70 expression induces antitumor immunity during intracellular hyperthermia using magnetite nanoparticles. Cancer Immunol Immunother 2003;52:80-8.
19. Todryk S, Melcher AA, Hardwick N, Linardakis E, Bateman A, Colombo MP, Stoppacciaro A, Vile RG. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol 1999;163:1398-1408.
20. Noessoner E, Gastpar R, Milani V, Brandi A, Hutzler RJS, Kuppner MC, Roos M, Kremmer E, Asea A, Calderwood SK, Issels RD. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunol 2002;169: 5424-32.
21. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kB pathway. Int Immunol 2000;12:1539-46.
22. Campici J, Leem TD, Fleshner M. Stress-induced extracellular Hsp72 is a functionally significant danger signal to the immune system. Cell Stress Chaperones 2003;8:272-86.
23. Winzler C, Rovere P, Rescigno M, Granucci F, Penna G, Adorini L, Zimmermann VS, Davoust J, Ricciardi-Castagnoli P. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med 1997;20:317-28.
24. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;68:328-32.
25. Reeves ME, Royal RE, Lam JS, Rosenberg SA, Hwu P. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res 1996;56:5672-7.
26. Nair SK, Snyder D, Rouse BT, Gilboa E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 1997;70:706-15.
27. Tjandrawan T, Martin DM, Maeurer MJ, Castelli C, Lotze MT, Storkus WJ. Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro. J Immunother 1998;21:149-57.
28. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1997; 183:87-97.
29. Tuting T, Wilson CC, Martin DM, Kasamon YL, Rowles J, Ma DI, Slingluff CL, Wagner SN, Van der Bruggen P, Baar J, Lotze MT, Storkus WJ. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. J Immunol 1998;160:1139-47.
30. Akasaki Y, Kikuchi T, Homma S, Abe T, Kufe D, Ohno T. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J Immunother 2001; 24:106-13.
31. Homma S, Toda G, Gong J, Kufe D, Ohno T. Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J Gastroenterol 2001;36:764-71.
32. Celluzzi CM, Falo LD. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J. Immunol 1998;160: 3081-5.
33. Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin-12. Cancer Res 1999;59:4035-41.
34. Kikuchi T, Miyazawa N, Moore MA, Crystal RG. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells. Cancer Res 2000;60: 6391-5.
35. Ito A, Shinkai M, Bouhon IA, Honda H, Kobayashi T. Induction of TNF-α gene expression by heat inducible promoter gadd 153. Jpn J Hyperthermic Oncol 2000;16:91-6.
36. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM. Generation of large Numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992;176: 1693-702.
37. Kikuchi T, Akasaki Y, Abe T, Ohno T. Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model. Cancer Immunol Immunother 2002;51: 424-30.
38. Chen CH, Wang TL, Hung CF, Yang Y, Young RA, Pardoll DM, Wu TC. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000;60:1035-42.
39. Ito A, Tanaka K, Kondo M, Shinkai M, Honda H, Matsumoto K, Saida T, Kobayashi T. Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma. Cancer Sci 2003;94: 308-13.
40. Ito A, Nakahara Y, Tanaka K, Kuga Y, Honda H, Kobayashi T. Time course of biodistribution and heat generation of magnetite cationic liposomes in mouse model. Jpn J Hyperthermic Oncol 2003;19: 151-59.
41. Yonezawa M, Ohtsuka T, Matsui N, Tsuji H, Kato KH, Moriyama A, Kato T. Hyperthermia induces apoptosis in malignant fibrous histiocytoma cells in vitro. Int J Cancer 1996;66:347-51.
42. Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile MJ. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 1998; 4:581-7.
43. Wells AD, Rai SK, Salvato MS, Band H, Malkovsky M. Hsp72-mediated augmentation of MHC class I surface expression and endogenous antigen presentation. Int Immunol 1998;10:609-17.
44. Hirao M, Onai N, Hiroishi K, Watkins SC, Matsushima K, Rohhins PD, Lotze MT, Tahara H. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res 2000;60:2209-17.
45. Geldhof AB, Moser M, Lespagnard L, Thielemans K, De Baetselier P. Interleukin-12-activated natural killer cells recognize B7 costimulatory molecules on tumor cells and autologous dendritic cells. Blood 1998;91:196-206.
46. Yu Y, Hagihara M, Ando K, Gansuvd B, Matsuzawa H, Tsuchiya T, Ueda Y, Inoue H, Hotta T, Kato S. Enhancement of human cord blood CD34+ cell-derived NK cell cytotoxicity by dendritic cells. J Immunol 2001;166:1590-1600.
47. Udono H, Srivastava PK. Comparison of tumor-specific immunogenicities of stress-induced protein gp96, hsp90, and hsp70. J Immunol 1994;152:5398-5403.